Firefly Neuroscience, Inc. (NASDAQ:AIFF) Sees Large Growth in Short Interest

Firefly Neuroscience, Inc. (NASDAQ:AIFF) was the target of a significant growth in short interest in September. As of September 30th, there was short interest totaling 1,098,284 shares, a growth of 265.0% from the September 15th total of 300,863 shares. Currently, 7.5% of the shares of the stock are short sold. Based on an average daily volume of 14,576,030 shares, the short-interest ratio is currently 0.1 days.

Institutional Investors Weigh In On Firefly Neuroscience

An institutional investor recently raised its stake in Firefly Neuroscience stock. Cygnus Capital Advisors LLC raised its holdings in shares of Firefly Neuroscience, Inc. (NASDAQ:AIFF) by 122.3% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 44,552 shares of the company’s stock after buying an additional 24,513 shares during the quarter. Cygnus Capital Advisors LLC owned about 0.28% of Firefly Neuroscience worth $54,000 as of its most recent SEC filing. 4.96% of the stock is currently owned by institutional investors and hedge funds.

Firefly Neuroscience Stock Performance

Shares of NASDAQ:AIFF traded down $0.02 during trading on Friday, reaching $1.19. The stock had a trading volume of 101,001 shares, compared to its average volume of 8,328,871. The business has a fifty day moving average price of $1.19 and a 200-day moving average price of $1.47. The stock has a market cap of $18.67 million, a PE ratio of -2.02 and a beta of 0.51. Firefly Neuroscience has a 1-year low of $0.62 and a 1-year high of $3.15.

Firefly Neuroscience (NASDAQ:AIFF) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.10) EPS for the quarter. Firefly Neuroscience had a negative return on equity of 90.17% and a negative net margin of 506.23%. The firm had revenue of $0.51 million for the quarter.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on AIFF. Wall Street Zen downgraded shares of Firefly Neuroscience from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Firefly Neuroscience in a research note on Friday, August 14th. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat, the stock presently has a consensus rating of “Sell”.

About Firefly Neuroscience

Firefly Neuroscience, Inc is a medical technology company focused on applying artificial intelligence to brain health and cognitive assessment. Its principal product is the Brain Network Analytics (BNA) platform, which analyzes electroencephalogram (EEG) data to generate insights into brain function and cognitive performance.

The BNA platform is designed to support clinicians, researchers and pharmaceutical companies in evaluating cognitive impairment and monitoring changes in brain health.